ArticleDiscover oncology2026
The value of plasma levels of heat shock protein 90α for predicting the treatment efficacy and prognosis of lung cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the value of heat shock protein 90α (HSP90α) in predicting treatment response and progression-free survival (PFS) among patients with lung cancer.
methodsWe retrospectively analyzed 585 patients with lung cancer treated at Jilin Cancer Hospital between January 2014 and December 2023. Patients were categorized by pretreatment HSP90α levels into high- and low-level groups and by posttreatment changes after four cycles into increasing and decreasing groups. We assessed the association between baseline HSP90α levels and clinical characteristics, its correlation with treatment efficacy and PFS, and its combined predictive ability with classical tumor biomarkers (CEA, NSE, and SCC).
resultsHigh pretreatment HSP90α levels were associated with older age and specific pathological types and served as an independent risk factor for shorter PFS. Patients with low baseline HSP90α levels exhibited a better short-term treatment response and longer PFS than did those with high baseline HSP90α levels. Increasing HSP90α after treatment correlated with an improved response and prolonged PFS. HSP90α levels were positively correlated with CEA, NSE, and SCC levels. Notably, the combination of HSP90α and CEA expression significantly enhanced PFS prediction in patients with lung adenocarcinoma.
conclusionsHSP90α is a significant predictive biomarker for treatment efficacy and prognosis in lung cancer patients, particularly when it is combined with traditional markers such as CEA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.